Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis
Year: 2026
Type: article
Study design: Observational Study
Authors: Kitsada Wudhikarn, Lohith Gowda, Qiran Ye, Temitope Oloyede, Michael Martens, Rahul Banerjee, Srinivas S. Devarakonda, Hongtao Liu, Megan M. Herr, Jo-Anne H. Young, Tania Jain, Ajoy Dias, Taiga Nishihori, Abu-Sayeef Mirza, Siddhartha Ganguly, Amer M. Beitinjaneh, Mahmoud Aljurf, Baldeep Wirk, Nosha Farhadfar, Yvonne A. Efebera, Miguel-Angel Perales, Christen L. Ebens, Hemant S Murthy, Joshua A. Hill, Christopher E. Dandoy, Sanghee Hong, Zeinab El Boghdadly, Othman Salim Akhtar, Jeffery J. Auletta, Anna R. Huppler, Muhammad Bilal Abid
Institutions: Chulalongkorn University, Yale Cancer Center, Yale University, Medical College of Wisconsin, Fred Hutch Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, University of Wisconsin–Madison, Roswell Park Comprehensive Cancer Center, University of Minnesota, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, National Institutes of Health, Moffitt Cancer Center, Houston Methodist, University of Miami Hospital, Sylvester Comprehensive Cancer Center, King Faisal Specialist Hospital & Research Centre, Virginia Commonwealth University, VCU Massey Comprehensive Cancer Center, OhioHealth, Memorial Sloan Kettering Cancer Center, Mayo Clinic, Mayo Clinic in Florida, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Duke University, Duke Medical Center, Wake Forest University, Nationwide Children's Hospital, National Marrow Donor Program, Texas Tech University, Texas Tech University Health Sciences Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: Cancer Center Support Grant, A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research, Clinical and mechanistic studies defining optimal preparative approaches to infants with IL2RG/JAK3/RAG1/RAG2 SCID: a randomized trial of busulfan dosage, BMT Core - Pediatric Transplantation and Cellular Therapy Consortium (PTCTC): Providing Clinical Trial Access For Children With Life Threatening Diseases
OpenAlex ID: W7166354902